Heron Therapeutics Inc (HRTX)
NASDAQ:HRTX
Want to see HRTX full AI Analyst Report?
HRTX Stock Chart & Stats
$1.00
-$0.05(-2.96%)
At close: 4:00 PM EST
$1.00
-$0.05(-2.96%)
Day’s Range― - ―
52-Week Range$0.42 - $2.30
Previous CloseN/A
Volume327.52K
Average Volume (3M)3.53M
Market Cap
$80.90M
Enterprise Value$252.94M
Total Cash (Recent Filing)$44.78M
Total Debt (Recent Filing)$141.63M
Price to Earnings (P/E)―
Beta1.53
Next Earnings
Aug 11, 2026EPS Estimate
>-0.01Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.18
Shares Outstanding189,279,370
10 Day Avg. Volume5,232,392
30 Day Avg. Volume3,528,072
Financial Highlights & Ratios
PEG Ratio-0.31
Price to Book (P/B)15.12
Price to Sales (P/S)1.40
P/FCF Ratio-7.77
Enterprise Value/Market Cap3.13
Enterprise Value/Revenue1.68
Enterprise Value/Gross Profit2.36
Enterprise Value/Ebitda-12.30
Forecast
1Y Price Target
$2.00Price Target Upside100.00% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering2
EPS Forecast (FY)-0.03
Revenue Forecast (FY)$173.15M
Bulls Say, Bears Say
Bulls Say
Commercial Portfolio StrengthHeron's commercially approved portfolio spans perioperative (ZYNRELEF, APONVIE) and oncology supportive care (CINVANTI), creating diversified, recurring revenue streams tied to procedure volumes and hospital/clinic purchasing. This reduces binary clinical risk and supports cross-channel commercial leverage over the medium term.
Sustained Product AdoptionReported durable unit demand (ZYNRELEF +22% YoY; APONVIE +68% YoY) and a sequential recovery in March indicate scalable commercial traction. Backed by targeted IGNITE programs and planned salesforce expansion, this adoption momentum supports lasting revenue growth potential if execution continues.
Reimbursement & Guideline SupportPermanent J-code, widespread P&T approvals and A1 guideline inclusion materially improve formulary access and reimbursement predictability for APONVIE. These durable access levers reduce adoption friction, support steady uptake across accounts, and help stabilize medium-term revenue and pricing power.
Bears Say
High LeverageThe balance sheet shows a very thin equity cushion relative to total debt, producing extreme leverage. This constrains financial flexibility, raises refinancing and covenant risk, and increases the likelihood of dilutive capital raises if operating cash generation slips, impairing long-term optionality.
Negative Cash GenerationPersistent negative operating and free cash flow means the business is not self-funding. Continued external financing may be required to support salesforce growth, PFS launch and working capital, heightening execution and dilution risk and limiting the company's ability to reinvest sustainably.
Patent Invalidation RiskA court ruling invalidating asserted CINVANTI patents creates a structural risk of generic entrants and pricing erosion for a core oncology offering. While Heron plans to appeal, the decision materially raises medium-term competitive risk to CINVANTI's revenue and the durability of the oncology franchise.
Heron Therapeutics News
HRTX FAQ
What was Heron Therapeutics Inc’s price range in the past 12 months?
Heron Therapeutics Inc lowest stock price was $0.42 and its highest was $2.30 in the past 12 months.
What is Heron Therapeutics Inc’s market cap?
Heron Therapeutics Inc’s market cap is $80.90M.
When is Heron Therapeutics Inc’s upcoming earnings report date?
Heron Therapeutics Inc’s upcoming earnings report date is Aug 11, 2026 which is in 63 days.
How were Heron Therapeutics Inc’s earnings last quarter?
Heron Therapeutics Inc released its earnings results on May 11, 2026. The company reported -$0.04 earnings per share for the quarter, missing the consensus estimate of -$0.023 by -$0.017.
Is Heron Therapeutics Inc overvalued?
According to Wall Street analysts Heron Therapeutics Inc’s price is currently Undervalued.
Does Heron Therapeutics Inc pay dividends?
Heron Therapeutics Inc does not currently pay dividends.
What is Heron Therapeutics Inc’s EPS estimate?
Heron Therapeutics Inc’s EPS estimate is >-0.01.
How many shares outstanding does Heron Therapeutics Inc have?
Heron Therapeutics Inc has 189,279,370 shares outstanding.
What happened to Heron Therapeutics Inc’s price movement after its last earnings report?
Heron Therapeutics Inc reported an EPS of -$0.04 in its last earnings report, missing expectations of -$0.023. Following the earnings report the stock price went down -21.074%.
Which hedge fund is a major shareholder of Heron Therapeutics Inc?
Currently, no hedge funds are holding shares in HRTX
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Heron Therapeutics Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$2.00 (100.00% Upside)
$2.00 (100.00% Upside)
Blogger Sentiment
Neutral
HRTX Sentiment 50%
Sector Average ―
Sector Average ―
Hedge Fund Trend
Decreased
By 4.3M Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Negative
Last 7 Days ▼ 1.1%
Last 30 Days ▼ 10.1%
Last 30 Days ▼ 10.1%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-78.65%
12-Months-Change
Fundamentals
Return on Equity
-1115.29%
Trailing 12-Months
Asset Growth
4.44%
Trailing 12-Months
Company Description
Heron Therapeutics Inc
Heron Therapeutics, Inc. is a biotechnology firm dedicated to creating innovative therapies for critical patient requirements. The company leverages its proprietary Biochronomer drug delivery platform, an advanced system that enables the controlled release of various short-acting pharmacological agents. This technology ensures therapeutic concentrations are maintained for periods ranging from days to weeks following just a single administration. Among its commercialized products is SUSTOL (granisetron), an extended-release injectable designed to prevent both immediate and delayed nausea and vomiting triggered by moderately emetogenic chemotherapy, or specific anthracycline and cyclophosphamide combination therapies. Additionally, Heron markets CINVANTI, an intravenous formulation of aprepitant. CINVANTI, which acts as a substance P/neurokinin-1 receptor antagonist, is indicated for the prevention of acute and delayed chemotherapy-induced nausea and vomiting in patients undergoing highly or moderately emetogenic cancer chemotherapy. The company's development pipeline includes ZYNRELEF, an innovative dual-acting local anesthetic that combines bupivacaine, a local anesthetic, with a low dose of the nonsteroidal anti-inflammatory drug (NSAID) meloxicam in a single fixed-dose formulation. Also in development is HTX-019, an experimental therapy aimed at preventing postoperative nausea and vomiting (PONV). Furthermore, HTX-034 is being advanced for postoperative pain management and is currently undergoing Phase Ib/II clinical trials, notably in patients recovering from bunionectomy procedures. Originally established in 1983 as A.P. Pharma, Inc., the company adopted its current name, Heron Therapeutics, Inc., in January 2014. Its corporate headquarters are situated in San Diego, California.
HRTX Company Deck
HRTX Earnings Call
Q1 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call struck an overall positive tone: despite a weather-driven Q1 setback and temporary margin/EBITDA pressure, commercial momentum is clear across key products (ZYNRELEF, APONVIE, CINVANTI) with strong YoY demand growth, successful distributor incentive programs (IGNITE), clinical guideline endorsement for APONVIE, planned sales force expansions, and maintained full-year guidance. Management attributes most weaknesses to external, temporary factors and provided timelines for margin normalization and recovery, supporting confidence in achieving 2026 objectives.View all HRTX earnings summariesHRTX Stock 12 Month Forecast
Average Price Target
$2.00
▲(100.00% Upside)
Technical Analysis
Ocugen
―
Benitec Biopharma
―
Kodiak Sciences
―
Sagimet Biosciences, Inc. Class A
―
Neumora Therapeutics, Inc.
―
Ownership Overview
21.42% Insiders
8.16% Mutual Funds
54.08% Other Institutional Investors
7.83% Public Companies and
Individual Investors